Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302) Meeting Abstract

  

Authors:	Rathkopf, D. E.; Smith, M. R.; De Bono, J. S.; Logothetis, C.; Shore, N.; De Souza, P. L.; Fizazi, K.; Mulders, P.; Mainwaring, P. N.; Hainsworth, J. D.; Beer, T. M.; North, S. A.; Fradet, Y.; Griffin, T. W.; Park, Y. C.; Kheoh, T. S.; Small, E. J.; Scher, H. I.; Molina, A.; Ryan, C. J.
Abstract Title:	Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
Meeting Title:	49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	15 Suppl.
Meeting Dates:	2013 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-05-20
Language:	English
ACCESSION:	WOS:000335419601610
PROVIDER:	wos
DOI:	10.1200/jco.2013.31.15_suppl.5009
Notes:	Meeting Abstract: 5009 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/128768